^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Loqtorzi (toripalimab-tpzi)

    i
    Other names: JS001, JS-001, JS 001, TAB-001, TAB001, terepril monoclonal antibody, treipril monoclonal antibody, TAB 001
    Company:
    Apotex, Coherus Oncology, Dr. Reddy’s, Excellmab, Hikma, LEO Pharma, Shanghai Junshi Biosci
    Drug class:
    PD1 inhibitor
    Related drugs:
    19h
    Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Sun Yat-sen University
    New P2 trial
    |
    Avastin (bevacizumab) • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • epirubicin
    2d
    TD-NEOE3V3: Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=390, Not yet recruiting, Tang-Du Hospital | Initiation date: May 2025 --> Feb 2026
    Trial initiation date
    |
    cisplatin • docetaxel • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel
    2d
    FACT-TN: FMD and Neoadjuvant Chemo-immunotherapy in TNBC (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 negative + ER positive • HER-2 negative + HR negative
    |
    docetaxel • Loqtorzi (toripalimab-tpzi) • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    2d
    A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=450, Active, not recruiting, TJ Biopharma Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • Loqtorzi (toripalimab-tpzi) • uliledlimab (TJD5)
    3d
    A single-arm, single-center, prospective clinical study of trastuzumab emtansine combined with GEMOX regimen as first-line treatment for advanced biliary system tumors (ChiCTR2600117154)
    P=N/A, N=20, Completed, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
    New trial
    |
    Kadcyla (ado-trastuzumab emtansine) • Loqtorzi (toripalimab-tpzi)
    3d
    A Single-Arm Prospective Clinical Study on the Efficacy of Neoadjuvant Therapy with Toripalimab Combined with TP Regimen for Locally Advanced Head and Neck Tumors (ChiCTR2600117056)
    P=N/A, N=30, Not yet recruiting, The First People's Hospital of Yunnan Province; The First People's Hospital of Yunnan Province
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel
    3d
    Real-world Study of Toripalimab in the Application of Advanced Hepatocellular Carcinoma (ChiCTR2600116531)
    P=N/A, N=840, Not yet recruiting, Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University
    New trial
    |
    Loqtorzi (toripalimab-tpzi)
    3d
    A National Multicenter, Observational, Real-World Study of Chemotherapy Combined with Toripalimab for Triple-Negative Breast Cancer (ChiCTR2600116235)
    P=N/A, N=1000, Not yet recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
    New trial
    |
    Loqtorzi (toripalimab-tpzi)
    3d
    A single-arm, single-center clinical study of toripalimab as adjuvant therapy for high-risk clear cell renal cell carcinoma after radical nephrectomy (ChiCTR2500115679)
    P=N/A, N=100, Not yet recruiting, The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University
    New trial
    |
    Loqtorzi (toripalimab-tpzi) • Imjudo (tremelimumab-actl)
    3d
    Efficacy and Safety of Gemcitabine Combined with Toripalimab in Docetaxel-Refractory or -Intolerant Patients with Metastatic Castration-Resistant Prostate Cancer: A Prospective, Open-Label, Single-Arm Interventional Study (ChiCTR2500115002)
    P=N/A, N=43, Not yet recruiting, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University; Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
    New trial
    |
    gemcitabine • docetaxel • Loqtorzi (toripalimab-tpzi)
    3d
    A Single-center, Single-arm, Prospective Study on Neoadjuvant Therapy with Sequential AC (Doxorubicin and Cyclophosphamide) Followed by TP (Paclitaxel and Cisplatin) in Combination with Toripalimab for Early-stage Triple-negative Breast Cancer (ChiCTR2500114191)
    P=N/A, N=46, Recruiting, Thyroid and Breast Surgery Department of North Sichuan Medical College Affiliated Hospital; North Sichuan Medical College Affiliated Hospital
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • paclitaxel • Loqtorzi (toripalimab-tpzi) • doxorubicin hydrochloride • cyclophosphamide
    3d
    Toripalimab Combined with Lenvatinib for Postoperative Adjuvant Therapy in Non-Clear Cell Renal Cell Carcinoma with High Recurrence Risk: An Evaluation of Efficacy and Safety (ChiCTR2500113091)
    P=N/A, N=60, Not yet recruiting, The Third Medical Centre, Chinese PLA General Hospital; The Third Medical Centre, Chinese PLA General Hospital
    New trial
    |
    SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • FH (Fumarate Hydratase) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • TFEB (Transcription Factor EB 2)
    |
    Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi)